PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
33 hedge funds and large institutions have $106M invested in PDL BioPharma, Inc. in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 103 closing their positions.
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
66% less capital invested
Capital invested by funds: $310M → $106M (-$204M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
75% less funds holding
Funds holding: 132 → 33 (-99)
76% less call options, than puts
Call options by funds: $63K | Put options by funds: $268K
95% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 103
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Silver Point Capital
Greenwich,
Connecticut
|
+$42.3M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$12.7M |
| 3 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$1.54M |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
+$1.25M |
| 5 |
JC
JBF Capital
Aspen,
Colorado
|
+$957K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$30.9M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$29.4M |
| 3 |
Renaissance Technologies
New York
|
-$23.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$18.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16.6M |
PDLI Hedge Fund Activity: Q4 2020 in Review
33 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2020, worth a combined $106M — down 66% from $310M a quarter earlier.
Sellers outnumbered buyers: 103 funds closed out of PDLI and 5 opened new positions — a net loss of 98 holders — while 14 trimmed existing stakes and 5 added.
The largest buyer was Silver Point Capital, adding an estimated $42.3M. The largest seller was BlackRock, exiting entirely with an estimated $30.9M sold.
- 33 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2020, down from 132 in Q3 2020.
- Funds reported $106M of PDL BioPharma, Inc. stock for Q4 2020, down 66% quarter-over-quarter.
- 5 funds opened new PDL BioPharma, Inc. positions in Q4 2020 and 103 closed out, a net change of -98 holders.
- The largest PDL BioPharma, Inc. buyer in Q4 2020 was Silver Point Capital, an estimated $42.3M added.
- The largest PDL BioPharma, Inc. seller in Q4 2020 was BlackRock, an estimated $30.9M sold.
Based on aggregated 13F filings for Q4 2020.